Untargeted Profiling of Concordant/Discordant Phenotypes of High Insulin Resistance and Obesity To Predict the Risk of Developing Diabetes.

This study explores the metabolic profiles of concordant/discordant phenotypes of high insulin resistance (IR) and obesity. Through untargeted metabolomics (LC-ESI-QTOF-MS), we analyzed the fasting serum of subjects with high IR and/or obesity ( n = 64). An partial least-squares discriminant analysis with orthogonal signal correction followed by univariate statistics and enrichment analysis allowed exploration of these metabolic profiles. A multivariate regression method (LASSO) was used for variable selection and a predictive biomarker model to identify subjects with high IR regardless of obesity was built. Adrenic acid and a dyglyceride (DG) were shared by high IR and obesity. Uric and margaric acids, 14 DGs, ketocholesterol, and hydroxycorticosterone were unique to high IR, while arachidonic, hydroxyeicosatetraenoic (HETE), palmitoleic, triHETE, and glycocholic acids, HETE lactone, leukotriene B4, and two glutamyl-peptides to obesity. DGs and adrenic acid differed in concordant/discordant phenotypes, thereby revealing protective mechanisms against high IR also in obesity. A biomarker model formed by DGs, uric and adrenic acids presented a high predictive power to identify subjects with high IR [AUC 80.1% (68.9-91.4)]. These findings could become relevant for diabetes risk detection and unveil new potential targets in therapeutic treatments of IR, diabetes, and obesity. An independent validated cohort is needed to confirm these results.

[1]  F. Tinahones,et al.  Metabolomic insights into the intricate gut microbial–host interaction in the development of obesity and type 2 diabetes , 2015, Front. Microbiol..

[2]  Jasper Engel,et al.  Non-targeted UHPLC-MS metabolomic data processing methods: a comparative investigation of normalisation, missing value imputation, transformation and scaling , 2016, Metabolomics.

[3]  M. Patti,et al.  Bile acids, obesity, and the metabolic syndrome. , 2014, Best practice & research. Clinical gastroenterology.

[4]  Nigel W. Hardy,et al.  Proposed minimum reporting standards for chemical analysis , 2007, Metabolomics.

[5]  M. Tomita,et al.  Serum metabolomics reveals γ-glutamyl dipeptides as biomarkers for discrimination among different forms of liver disease. , 2011, Journal of hepatology.

[6]  Julian L Griffin,et al.  Metabolomics as a functional genomic tool for understanding lipid dysfunction in diabetes, obesity and related disorders. , 2006, Pharmacogenomics.

[7]  F. Tinahones,et al.  New and vintage solutions to enhance the plasma metabolome coverage by LC-ESI-MS untargeted metabolomics: the not-so-simple process of method performance evaluation. , 2015, Analytical chemistry.

[8]  M. Puig-Domingo,et al.  Prevención, diagnóstico y tratamiento de la obesidad. Posicionamiento de la Sociedad Española para el Estudio de la Obesidad de 2016 , 2016 .

[9]  David R. Gilbert,et al.  MetaNetter: inference and visualization of high-resolution metabolomic networks , 2008, Bioinform..

[10]  Ian D. Wilson,et al.  Metabolic Phenotyping in Health and Disease , 2008, Cell.

[11]  Andreas Krämer,et al.  Causal analysis approaches in Ingenuity Pathway Analysis , 2013, Bioinform..

[12]  K. Petersen,et al.  Lipid-induced insulin resistance: unravelling the mechanism , 2010, The Lancet.

[13]  David S. Wishart,et al.  Current Progress in computational metabolomics , 2007, Briefings Bioinform..

[14]  R. Holman,et al.  Normal weight individuals who develop type 2 diabetes: the personal fat threshold. , 2015, Clinical science.

[15]  Oliver Fiehn,et al.  Chemical Similarity Enrichment Analysis (ChemRICH) as alternative to biochemical pathway mapping for metabolomic datasets , 2017, Scientific Reports.

[16]  Hae-Young Kim,et al.  Statistical notes for clinical researchers: Chi-squared test and Fisher's exact test , 2017, Restorative dentistry & endodontics.

[17]  F. Tinahones,et al.  The obese healthy paradox: is inflammation the answer? , 2010, The Biochemical journal.

[18]  G. Shulman,et al.  Diacylglycerol-mediated insulin resistance , 2010, Nature Medicine.

[19]  D. Levy,et al.  Glycemic status and development of kidney disease: the Framingham Heart Study. , 2005, Diabetes care.

[20]  G. Boden.  Insulin Resistance and Free Fatty Acids , 2011 .

[21]  Tim D. Spector,et al.  Mixing omics: combining genetics and metabolomics to study rheumatic diseases , 2017, Nature Reviews Rheumatology.

[22]  Bhawna Singh,et al.  Surrogate markers of insulin resistance: A review. , 2010, World journal of diabetes.

[23]  R. A. van den Berg,et al.  Centering, scaling, and transformations: improving the biological information content of metabolomics data , 2006, BMC Genomics.

[24]  J. Cabral,et al.  Hyporeninemic hypoaldosteronism and diabetes mellitus: Pathophysiology assumptions, clinical aspects and implications for management. , 2016, World journal of diabetes.

[25]  Y. Tsai,et al.  The metabolome profiling and pathway analysis in metabolic healthy and abnormal obesity , 2015, International Journal of Obesity.

[26]  M. Urpi-Sardà,et al.  Comparative analysis of sample preparation methods to handle the complexity of the blood fluid metabolome: when less is more. , 2013, Analytical chemistry.

[27]  V. Mootha,et al.  Metabolite profiles and the risk of developing diabetes , 2011, Nature Medicine.

[28]  O. Monte,et al.  Cholesterol oxides as biomarkers of oxidative stress in type 1 and type 2 diabetes mellitus , 2007, Diabetes/metabolism research and reviews.

[29]  F. Karpe,et al.  Fatty Acids, Obesity, and Insulin Resistance: Time for a Reevaluation , 2011, Diabetes.

[30]  J. Gómez-Ariza,et al.  Iberian ham typification by direct infusion electrospray and photospray ionization mass spectrometry fingerprinting. , 2012, Rapid communications in mass spectrometry : RCM.

[31]  R. Tibshirani.  Regression Shrinkage and Selection via the Lasso , 1996 .

[32]  F. Tinahones,et al.  Metabolomics‐guided insights on bariatric surgery versus behavioral interventions for weight loss , 2016, Obesity.

[33]  Satoru Kodama,et al.  Association Between Serum Uric Acid and Development of Type 2 Diabetes , 2009, Diabetes Care.

[34]  T. Azuma,et al.  Adrenic acid as an inflammation enhancer in non-alcoholic fatty liver disease. , 2017, Archives of biochemistry and biophysics.

[35]  V. Mootha,et al.  Metabolite profiles and the risk of developing diabetes , 2011, Nature Network Boston.

[36]  I. Bondia-Pons,et al.  Oxidative stress and inflammation interactions in human obesity , 2012, Journal of Physiology and Biochemistry.

[37]  Alexandre Perera-Lluna,et al.  An R package to analyse LC/MS metabolomic data: MAIT (Metabolite Automatic Identification Toolkit) , 2014, Bioinform..

[38]  Jean-François Hocquette,et al.  Assessment of hierarchical clustering methodologies for proteomic data mining. , 2007, Journal of proteome research.

[39]  2. Classification and Diagnosis of Diabetes , 2014, Diabetes Care.

[40]  F. Tinahones,et al.  Biomarkers of Morbid Obesity and Prediabetes by Metabolomic Profiling of Human Discordant Phenotypes. , 2016, Clinica chimica acta; international journal of clinical chemistry.

[41]  F. Tinahones,et al.  Adipose tissue infiltration in normal-weight subjects and its impact on metabolic function. , 2016, Translational research : the journal of laboratory and clinical medicine.

[42]  D. Fairlie,et al.  Inflammatory lipid mediators in adipocyte function and obesity , 2010, Nature Reviews Endocrinology.

[43]  Cristina Andres-Lacueva,et al.  Plasma metabolomic biomarkers of mixed nuts exposure inversely correlate with severity of metabolic syndrome. , 2015, Molecular nutrition & food research.

[44]  M. Lanaspa,et al.  Uric acid in metabolic syndrome: From an innocent bystander to a central player. , 2016, European journal of internal medicine.